Premium
Frequent occurrence of p 53 mutations in rhabdomyosarcoma and leiomyosarcoma, but not in fibrosarcoma and malignant neural tumors
Author(s) -
Würl Peter,
Taubert Helge,
Bache Matthias,
Kroll Jens,
Meye Axel,
Berger Dieter,
Siermann Anja,
Holzhausen HansJürgen,
Hinze Raoul,
Schmidt Hannelore,
Rath FriedrichWilhelm
Publication year - 1996
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19960822)69:4<317::aid-ijc14>3.0.co;2-2
Subject(s) - leiomyosarcoma , immunohistochemistry , rhabdomyosarcoma , fibrosarcoma , sarcoma , biology , pathology , mdm2 , cancer research , tumor suppressor gene , carcinogenesis , gene , medicine , genetics
Abstract We have analyzed soft‐tissue sarcomas (STS) molecularly for mutations in the tumor‐suppressor gene p53 and immunohistochemically for expression of p53 and mdm2 proteins. In this study, tumor samples from 3 groups of soft‐tissue sarcomas, i.e., fibrosarcomas, myogenic sarcomas and malignant neural tumors (MNT), were investigated. The methods applied encompass immunohistochemistry on 198 tumor samples using p53 antibodies (DO‐1 and DO‐7) and an mdm2 antibody (IF‐2). Out of these, 100 samples were subjected to non‐radioactive PCR‐SSCP‐sequencing analysis. Immunohistochemical detection rate for p53 (range of 57% to 67%) and for mdm2 proteins (range of 19 to 44%) was similar in all 3 groups. In higher tumor grades, an increased rate of immunopositivity was found for p53 but not for mdm2. Investigation of p53 mutational status revealed 6 mutations in myogenic sarcomas but none in malignant neural tumors or fibrosarcomas, suggesting different roles of p53 in the 3 STS groups. Interestingly, a G A transition in codon 245 (a CpG site) was found in 3 myogenic sarcomas. Our results and those of others suggest p53 codon 245 as a mutational hotspot in sarcomas, as recognized in carcinomas. © 1996 Wiley‐Liss, Inc.